Cortisol as biomarker for CYP17 inhibition in mCRPC patients treated with abiraterone acetate.

M.A.C. Bruin,Merel van Nuland,Bart A. W. Jacobs,Andre M. Bergman,Hilde Rosing,Jos H. Beijnen,Alwin D. R. Huitema

Cortisol as biomarker for CYP17 inhibition in mCRPC patients treated with abiraterone acetate.

2021

M.A.C. Bruin
Merel van Nuland
Bart A. W. Jacobs
Andre M. Bergman
Hilde Rosing
Jos H. Beijnen
Alwin D. R. Huitema

5035Background: Abiraterone acetate is an effective metastatic castration resistant prostate cancer (mCRPC) treatment, however, there is a high variability in response. It inhibits CYP17, thereby p...

Keywords:

castration resistant
Medicine
Internal medicine
Oncology
Biomarker (medicine)
Prostate cancer
Abiraterone acetate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations